Q-omics provides the consensus-scored RN7SL683P profile across patient tissues and cancer cell-line models. RN7SL683P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RN7SL683P is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, RN7SL683P RNA expression shows 6,786 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LIHC, BRCA, and LAML as cancer lineages where RN7SL683P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL683P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL683P survival associations across molecular data types. RN7SL683P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL683P RNA expression–survival associations across cancer types. High RN7SL683P expression shows unfavorable associations in LIHC, LGG, COAD, SKCM and READ, but favorable associations in ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RN7SL683P RNA expression.
This table summarizes RN7SL683P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL683P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL683P shows lower tumor expression in BRCA. The BRCA box plot shows higher RN7SL683P RNA expression in normal versus tumor tissue (log2 FC = −0.137, t-test p = .006).
This table shows molecular features associated with RN7SL683P in patient tissues and cancer cell lines. In patient samples, RN7SL683P shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
